QUÉBEC CITY, Nov. 16, 2015
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that the holders of its issued and
outstanding common shares ("Common Shares") approved a share
consolidation (the "Consolidation") and that the Company has
determined that the Consolidation ratio will be
100-for-1.
Representatives of Computershare Trust Company of Canada, who served as the scrutineers of the
special meeting of shareholders at which the Consolidation was
approved, certified that 333,889,035 of the Company's Common Shares
were voted on the Consolidation, that 235,979,275 shares were voted
in favor of the Consolidation (representing 70.68% of the shares
voted) and that 97,909,760 shares were voted against the
Consolidation (representing 29.32% of the shares voted). The
votes cast in favor of the Consolidation therefore satisfied the
requirement that the Consolidation be approved by not less than
two-thirds of the votes cast by shareholders who voted in respect
of the Consolidation.
The Company intends to implement the Consolidation in the coming
days and will shortly provide all relevant details regarding the
Consolidation, including its effective date and the date on which
the Common Shares are expected to commence trading on a
post-Consolidation basis on the NASDAQ Capital Market and the
Toronto Stock Exchange and information for registered and
beneficial shareholders to exchange their pre-Consolidation for
post-Consolidation Common Shares.
The Company also announces that Mr. Marcel Aubut is no longer a member of the Board
of Directors effective today, November 16,
2015.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women's health. For more
information, visit www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.